Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most. Diffusion's lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine's most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion's product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.

Company profile
Ticker
DFFN
Exchange
Website
CEO
Robert J. Cobuzzi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
FERIS INTERNATIONAL, INC., RestorGenex Corp, Stratus Media Group, Inc, TITAN MOTORCYCLE CO OF AMERICA INC
SEC CIK
Corporate docs
Subsidiaries
Canterbury Laboratories, LLC • Hygeia Therapeutics, Inc. • Diffusion Pharmaceuticals LLC ...
IRS number
300645032
DFFN stock data
News
Diffusion Pharmaceuticals To Initiate Phase 2 Trial In Patients With Glioblastoma Multiforme Incorporating Innovative Imaging Methodology To Evaluate Tumor Oxygenation
26 Jul 22
Diffusion Pharmaceuticals Announces Effects In Altitude Trial
23 Jun 22
DFFN: Data from Altitude Trial Expected in June 2022…
25 May 22
Press releases
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
11 Aug 22
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
26 Jul 22
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
23 Jun 22
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
18 May 22
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
17 May 22
Investment data
Securities sold
Number of investors
Calendar
11 Aug 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.97M | 5.97M | 5.97M | 5.97M | 5.97M | 5.97M |
Cash burn (monthly) | 1.3M | 3.11M | 1.42M | 2.08M | 1.34M | 1.23M |
Cash used (since last report) | 1.89M | 4.52M | 2.05M | 3.02M | 1.94M | 1.78M |
Cash remaining | 4.08M | 1.45M | 3.91M | 2.95M | 4.03M | 4.18M |
Runway (months of cash) | 3.1 | 0.5 | 2.8 | 1.4 | 3.0 | 3.4 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Aug 22 | Cobuzzi Robert Joseph Jr. | Common Stock | Sale back to company | Dispose D | No | No | 0 | 121 | 0 | 1,204 |
1 Aug 22 | Cobuzzi Robert Joseph Jr. | Common Stock | Option exercise | Acquire M | No | No | 0 | 327 | 0 | 1,325 |
1 Aug 22 | Cobuzzi Robert Joseph Jr. | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 327 | 0 | 654 |
31 May 22 | Jane H Hollingsworth | Common Stock | Sale back to company | Dispose D | No | No | 0 | 67 | 0 | 771 |
31 May 22 | Jane H Hollingsworth | Common Stock | Option exercise | Acquire M | No | No | 0 | 183 | 0 | 838 |
31 May 22 | Jane H Hollingsworth | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 183 | 0 | 915 |
2 May 22 | Cobuzzi Robert Joseph Jr. | Common Sock | Sale back to company | Dispose D | No | No | 0 | 121 | 0 | 998 |
2 May 22 | Cobuzzi Robert Joseph Jr. | Common Stock | Option exercise | Acquire M | No | No | 0 | 327 | 0 | 1,119 |
2 May 22 | Cobuzzi Robert Joseph Jr. | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 327 | 0 | 981 |
18 Apr 22 | Cobuzzi Robert Joseph Jr. | Common Stock | Conversion | Acquire C | No | No | 25 | 100 | 2.5K | 792 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Financial report summary
?Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
acid, acidity, adjuvant, affirmed, agent, aggressive, arterial, ascent, BTIG, cellular, concomitant, core, crossover, deadly, endeavor, escalation, experimental, feet, fulfill, imaging, Instruction, investigate, investigated, July, lactate, lactic, LLC, magnetic, malignant, metabolic, Methodology, notable, partnership, percent, PET, ph, population, preserve, reinforce, resonance, respiratory, rest, risky, sea, stressful, structure, suffering, survival, temozolomide, type, ultimate, wash, week, winding
Removed:
base, cancer, half, improve, pathway, portion, reduce, Section, topline
Financial reports
Current reports
8-K
Other Events
27 Jul 22
8-K
Entry into a Material Definitive Agreement
22 Jul 22
8-K
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
28 Jun 22
8-K
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
23 May 22
8-K
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
15 May 22
8-K
Other Events
4 May 22
8-K
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan
18 Apr 22
8-K
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
12 Apr 22
8-K
Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders
8 Apr 22
8-K
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
21 Mar 22
Registration and prospectus
S-8
Registration of securities for employees
12 Aug 22
424B5
Prospectus supplement for primary offering
22 Jul 22
S-8
Registration of securities for employees
12 Aug 21
424B5
Prospectus supplement for primary offering
16 Feb 21
FWP
Free writing prospectus
11 Feb 21
FWP
Free writing prospectus
11 Feb 21
424B5
Prospectus supplement for primary offering
11 Feb 21
424B2
Prospectus for primary offering
2 Oct 20
S-3
Shelf registration
25 Sep 20
424B3
Prospectus supplement
8 Jun 20
Proxies
DEFA14A
Additional proxy soliciting materials
8 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Mar 22
PRE 14A
Preliminary proxy
18 Feb 22
DEFA14A
Additional proxy soliciting materials
21 Jun 21
DEFA14A
Additional proxy soliciting materials
20 May 21
DEF 14A
Definitive proxy
29 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
Other
EFFECT
Notice of effectiveness
5 Oct 20
CORRESP
Correspondence with SEC
29 Sep 20
UPLOAD
Letter from SEC
28 Sep 20
EFFECT
Notice of effectiveness
11 Jun 20
CORRESP
Correspondence with SEC
2 Jun 20
UPLOAD
Letter from SEC
1 Jun 20
EFFECT
Notice of effectiveness
30 Dec 19
CORRESP
Correspondence with SEC
22 Dec 19
UPLOAD
Letter from SEC
22 Dec 19
EFFECT
Notice of effectiveness
14 Nov 19
Ownership
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
3 Aug 22
4
Diffusion Pharmaceuticals / Jane H Hollingsworth ownership change
2 Jun 22
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
3 May 22
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
19 Apr 22
4
Diffusion Pharmaceuticals / WILLIAM ROBERT ELDER ownership change
19 Apr 22
4
Diffusion Pharmaceuticals / WILLIAM ROBERT ELDER ownership change
22 Mar 22
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
22 Mar 22
4/A
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
2 Feb 22
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
2 Feb 22
4
Diffusion Pharmaceuticals / William Karl Hornung ownership change
31 Jan 22
Patents
Utility
Trans carotenoids, their synthesis, formulation and uses
22 Mar 22
The invention relates to trans carotenoid compounds and salts thereof as well as compositions thereof, methods for making them, and uses thereof.
Utility
Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
30 Nov 21
The subject disclosure relates to compounds and compositions including chemotherapy agents and/or radiation therapy with bipolar trans carotenoids, and the use of such compounds for the treatment of various cancers including pancreatic and brain cancers.
Utility
Diffusion enhancing compounds and their use alone or with thrombolytics
19 Oct 21
The subject invention relates to diffusion enhancing compounds and their use alone or with thrombolytic agents for the treatment of disorders resulting from the formation of a thrombus such as a myocardial infarction or stroke.
Utility
Diffusion Enhancing Compounds and Their Use with Thrombectomy and Embolectomy and Other Vascular Disease Procedures
12 Aug 21
The subject invention relates to novel methods for the rapid treatment of disorders resulting from thrombosis or embolism such as a myocardial infraction or stroke.
Reddit threads
Daily Discussion Thread - August 10th, 2022
10 Aug 22
Daily Discussion Thread - August 9th, 2022
9 Aug 22
Daily Discussion Thread - May 13th, 2022
13 May 22
Daily Discussion Thread - May 9th, 2022
9 May 22
Daily Discussion Thread - May 6th, 2022
6 May 22
DFFN is above 8$
19 Apr 22
Daily Discussion Thread - March 22nd, 2022
22 Mar 22
5 Promising Biotech Penny Stocks To Keep An Eye On
17 Mar 22
Daily Discussion Thread - March 16th, 2022
16 Mar 22
Daily Discussion Thread - March 15th, 2022
15 Mar 22